Editorial
Copyright ©The Author(s) 2024.
World J Gastrointest Endosc. Apr 16, 2024; 16(4): 178-186
Published online Apr 16, 2024. doi: 10.4253/wjge.v16.i4.178
Table 1 Current commercially-available endoscopic bariatric therapies within the United States
Endoscopic bariatric therapies
Food and Drug Administration authorized
    ESG with Apollo ESGTM
    Transoral outlet reduction with Apollo reviseTM
    Orbera® intragastric balloon
    Spatz3 intragastric balloon
Off-label or experimental procedures
    Endoscopic gastroplasty with Endomina®*
    Primary obesity surgery endoluminal 2.0 procedure with incisionless operating platform®*
    Endoscopic revision of vertical sleeve gastrectomy (with Apollo OverStitchTM, Endomina®, or the incisionless operating platform®)